Cancer Research Meeting Calendar Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanaka, T.
Right arrow Articles by Hosokawa, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanaka, T.
Right arrow Articles by Hosokawa, M.
[Cancer Research 61, 2424-2428, March 15, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

Ligands for Peroxisome Proliferator-activated Receptors {alpha} and {gamma} Inhibit Chemically Induced Colitis and Formation of Aberrant Crypt Foci in Rats1

Takuji Tanaka2,,3, Hiroyuki Kohno2, Shin-ichiro Yoshitani, Shigeki Takashima, Ataru Okumura, Akira Murakami and Masashi Hosokawa

Departments of Pathology [T. T., H. K.] and General and Gastrointestinal Surgery [S-i. Y., S. T.], Kanazawa Medical University, Ishikawa 920-0293; Department of Endocrinological Metabolism, Anjo Kosei Hospital, Aichi 446-8602 [A. O.]; Department of Biotechnological Science, Faculty of Biology-Oriented Science and Technology, Kinki University, Wakayama 649-6493 [A. M.]; and Graduate School of Fisheries Sciences, Hokkaido University, Hokkaido 041-8611 [M. H.], Japan


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
The biological role of the peroxisome proliferator-activated receptors (PPARs) in various diseases, including inflammation and cancer, has been highlighted recently. Although PPAR{gamma} ligands have been found to inhibit mammary carcinogenesis in rodents, the effects on colon tumorigenesis are controversial. In the present study, three different experiments were conducted to investigate the modifying effects of PPARs ligands (PPAR{alpha} and PPAR{gamma}) on colitis and an early phase of colitis-related colon carcinogenesis in male F344 rats. In the first experiment, gastric gavage of troglitazone (PPAR{gamma} ligand, 10 or 100 mg/kg body weight) or bezafibrate (PPAR{alpha} ligand, 10 or 100 mg/kg body weight) inhibited colitis induced by dextran sodium sulfate (DSS) and lowered trefoil factor-2 content in colonic mucosa. In the second experiment, dietary administration (0.01 or 0.05% in diet) of troglitazone and bezafibrate for 4 weeks significantly reduced azoxymethane (AOM, two weekly s.c. injections, 20 mg/kg body weight)-induced formation of aberrant crypts foci, which are precursor lesions for colon carcinoma. In the third experiment, dietary administration (0.01% in diet for 6 weeks) of pioglitazone (PPAR{gamma} ligand), troglitazone, and bezafibrate effectively suppressed DSS/AOM-induced ACF. Administration of both ligands significantly reduced cell proliferation activity in colonic mucosa exposed to DSS and AOM. Our results suggest that synthetic PPARs ligands (PPAR{alpha} and PPAR{gamma}) can inhibit the early stages of colon tumorigenesis with or without colitis.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
Patients with long-standing ulcerative colitis are at increased risk of developing colorectal cancer compared with the general population (1) . Thus, prevention of colonic malignancy by inhibition of ulcerative colitis is an attractive approach in the overall management of colonic cancer (2 , 3) .

Acute and chronic inflammatory processes may be important among the factors involved in oxidative events leading to DNA damage in the colorectal epithelium (4) . DSS4 can be used to induce both acute and chronic colonic inflammations, depending on the dose and duration of treatment (5) . Long-term administration of DSS induces colorectal cancer (6) , whereas short-term exposure results in the formation of ACF (7) , which are precursor lesions for colon adenocarcinoma (8, 9, 10) , and enhances the development colorectal cancer. Therefore, the DSS-induced colitis model is useful for studying colitis-associated colorectal neoplasia (3 , 11) .

Recently, the physiological function and metabolism of PPARs, which are members of the nuclear hormone receptor superfamily, as well as their role in various nutritional states and various diseases including inflammation and cancer have been highlighted (reviewed in Refs. 12, 13, 14, 15 ). PPARs bind to a specific element in the promoter region of target genes. PPAR and other nuclear hormone receptors bind the promoter only as a heterodimer with the receptor for 9-cis-retinoic acid, retinoid X receptor. They activate transcription in response to binding of the hormone (ligand). Eicosanoids and fatty acids can regulate gene transcription through PPARs. At present, several PPARs have been identified including PPAR{alpha}, PPARß (PPAR{delta}, NUC-1, or FAAR), and PPAR{gamma}. Some ligands, such as polyunsaturated fatty acids and probably oxidized fatty acids, are shared by the three isotypes. Several compounds including linoleic acid, phytanic acid, conjugated linolenic acid, 8S-hydroxyeicosatetraenoic acid, and leukotriene B4 bind with high affinity to PPAR{alpha}. PPARs are expressed in the intestine at various levels (16 , 17) . The ligands for PPAR{gamma} are suspected to modify carcinogenesis (15) . In colon carcinogenesis, conflicting results between in vivo (18 , 19) and in vitro (20) studies have been reported on the action of synthetic PPAR{gamma} agonists, troglitazone and rosiglitazone, used for the treatment of type II diabetes (21) . In vivo studies of other organs showed that GW7845, a new PPAR{gamma} ligand, could inhibit rat mammary carcinogenesis (22) . DuBois et al. (23) reported aberrant expression of PPAR{gamma} in chemically induced colonic carcinoma and human colon cancer cell lines. Similar to PPAR{alpha} (24) , PPAR{gamma} agonists 15-deoxy-{Delta}12,14-prostaglandin J2 and troglitazone exhibit anti-inflammatory properties (25 , 26) . Moreover, PPAR{gamma} ligand effectively inhibits colitis in mice (27) . Interestingly, NSAIDs including indomethacin, which are candidate chemopreventive agents against colon cancer, activate both PPAR{alpha} and PPAR{gamma} (28) .

Suppression of tumor growth in vitro (20) is not supported in animal models of familial adenomatous polyposis coli (18 , 19) . In the present study, we investigated the role of PPAR{alpha} and PPAR{gamma} ligands in preventing colitis induced by DSS and ACF induced by DSS and/or AOM in rats. Because TFF play an important role in the repair and healing of the gastrointestinal tract (29) , we measured TFF2 and TFF3 concentrations in the mucosa of rats with experimentally induced colitis. Because control of cell proliferation is important for cancer inhibition (30) , we also estimated the cell proliferation activity in colonic mucosa exposed to DSS, AOM, and PPARs ligands by counting the number of AgNOR protein per mucosal cell nucleus (AgNORs index). Our results showed that PPAR{alpha} and PPAR{gamma} ligands suppressed DSS-induced colitis and DSS- and/or AOM- induced ACF. This may explain the protective role of ligands for PPAR{alpha} and PPAR{gamma} against colonic ACF and suggests a possible therapeutic effect in colitis-associated colon carcinogenesis.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Animals, Chemicals, and Diets.
Male F344 rats (Shizuoka Laboratory Animal Center, Shizuoka, Japan), 4 weeks of age, were used in three different experiments. The animals were maintained at Kanazawa Medical University Animal Facility according to the Institutional Animal Care Guidelines. All animals were housed in plastic cages (three or four rats/cage) with free access to drinking water and a basal diet, CE-2 (CLEA Japan Inc., Tokyo, Japan), under controlled conditions of humidity (50 ± 10%), light (12/12 h light/dark cycle), and temperature (23 ± 2°C). They were quarantined for the first 14 days and then randomized by body weight into experimental and control groups. DSS, with a molecular weight of 40,000, was purchased from ICN Pharmaceuticals, Inc. (Costa Mesa, CA). DSS for induction of colitis was dissolved in water at a concentration of 1% (w/v). AOM for induction of ACF was purchased from Sigma Chemical Co. (St. Louis, MO). Powdered CE-2 diet was used as a basal diet throughout the study. PPARs ligands tested included PPAR{gamma} ligand troglitazone (Sankyo Co., Tokyo), PPAR{gamma} ligand pioglitazone (Takeda Chemical Industries, Osaka, Japan), and PPAR{alpha} ligand bezafibrate (Kissei Pharmaceutical Co., Matsumoto, Japan). Experimental diets containing troglitazone, pioglitazone, and bezafibrate were prepared by mixing the respective compound in powdered basal diet CE-2 at a concentration (w/w) of 0.01 or 0.05%.

Experimental Procedure.
Three experiments were conducted to examine the effects of PPAR ligands in rats with DSS-induced colitis, AOM-induced ACF, and DSS/AOM-induced ACF.

Experiment 1.
A total of 54 male F344 rats were divided into eight experimental and control groups (Fig. 1A)Citation . Groups 1–5 were provided with drinking water containing 1% DSS ad libitum for 7 days. Groups 2–5 also received gastric gavage of troglitazone (10 mg/kg body weight for group 2 or 100 mg/kg body weight for group 3) or bezafibrate (10 mg/kg body weight for group 4 or 100 mg/kg body weight for group 5) suspended in 0.75% methyl cellulose containing normal physiological solution every other day for 3 times, starting 24 h after commencement of the study. Groups 6 and 7 were treated with troglitazone and bezafibrate (100 mg/kg body weight), respectively. Group 8 represents untreated control rats. The experiment was terminated at day 8. All animals were sacrificed, and the colons were flushed with saline, excised, cut open longitudinally along the main axis, and then washed with saline. The colon was cut and fixed in 10% buffered formalin for at least 24 h. Histological examination was performed using paraffin-embedded sections after H&E staining. For statistical evaluation, the severity of colonic inflammation was histologically scored in a blind fashion according to the scoring system (31) : grade 0, normal; grade 1, focal inflammatory cell infiltration including neutrophils; grade 2, crypt loss with inflammatory cell infiltration or crypt abscess formation; grade 3, mucosal ulceration, or five or more foci of gland loss with inflammatory cell infiltration; and grade 4, two or more areas of mucosal ulceration. At the end of the study, the concentrations of TFF2 and TFF3 in the colonic mucosa of three rats from each group were measured by RIA (32) using region-specific polyclonal antibodies in each case. Total protein concentration was also determined using the protocol of Bradford (33) .



View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Experimental protocols. A, experiment 1; B, experiment 2; C, experiment 3. bw, body weight; i.g., intragastrically.

 
Experiment 2.
A total of 56 male F344 rats were divided into eight experimental and control groups (Fig. 1B)Citation . Groups 1–5 were treated with AOM by two weekly s.c. injections (20 mg/kg body weight). Rats in groups 2 and 3 were fed a diet containing 0.01 and 0.05% troglitazone, respectively, for 4 weeks, commencing 1 week before the first dose of AOM. Groups 4 and 5 were fed a diet mixed with 0.01 and 0.05% bezafibrate, respectively, for 4 weeks, commencing 1 week before the first injection of AOM. Groups 6 and 7 were given a diet containing 0.05% troglitazone and bezafibrate alone. Group 8 served as the untreated control. Rats were sacrificed at week 4 by ether overdose to assess the incidence of colonic ACF. The frequency of ACF was determined according to the method described in our previous report (10) . At necropsy, the colons were flushed with saline, excised, cut open longitudinally along the main axis, and then washed with saline. They were cut and fixed in 10% buffered formalin for at least 24 h. Fixed colons were dipped in 0.5% solution of methylene blue in distilled water for 30 s, briefly washed with distilled water, and placed on a microscope slide with the mucosal surface up. Using a light microscope at a magnification of x40, ACF were distinguished from the surrounding "normal-appearing" crypts by their large size (10) .

Experiment 3.
A total of 55 male F 344 rats were divided into nine experimental and control groups (Fig. 1C)Citation . Group 1 was administered two weekly s.c. injections of AOM on weeks 3 and 4 at a dose of 20 mg/kg body weight. Groups 2–5 were administered 1% DSS in drinking water for 7 days and two weekly s.c. injections of AOM (20 mg/kg body weight), commencing 7 days after DSS administration. Groups 3, 4, and 5 were fed diets containing 0.01% pioglitazone, troglitazone, and bezafibrate for 6 weeks, respectively. Groups 6–8 were administered diets mixed with 0.01% pioglitazone, troglitazone, and bezafibrate alone, respectively. Group 9 consisted of untreated control rats. The severity of colitis and development of ACF were evaluated at week 6, as described in Experiments 1 and 2. In addition, the AgNORs index was counted on one-step silver-stained sections (34) in four rats in each of groups 1–5 and in three rats in each of groups 6–9. Measurements were performed on 25 crypts/rat.

Statistical Analysis.
All data were expressed as mean ± SD. Data were compared by one-way ANOVA, followed by a Bonferroni/Dunn post-hoc test. P < 0.05 denoted the presence of a statistically significant difference.


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
Experiment 1.
The mean body weights of rats of groups 2–5, which were treated with 1% DSS and troglitazone or bezafibrate, were slightly lower than that of group 1 treated with 1% DSS alone at the end of the study (Table 1)Citation . The mean liver and relative liver weights did not differ among the groups. Scoring of severity of colitis showed significant reduction in groups 2–5, compared with group 1 (P < 0.005, P < 0.001, P < 0.02, and P < 0.002, respectively). The concentrations of TFF2 and TFF3 in colonic mucosa are shown in Table 2Citation . Although the concentrations of TFF3 were comparable among the groups, those of TFF2 in groups 2–5 were lower than that of group 1, and the value of group 3 was significantly smaller than group 1 (P < 0.05).


View this table:
[in this window]
[in a new window]

  		Table 1 Effects of PPARs ligands on DSS-induced colitis (experiment 1)

 

View this table:
[in this window]
[in a new window]

  		Table 2 Colonic tissue concentrations of endogenous TFF2 and TFF3 (experiment 1)

 
Experiment 2.
Body, liver, and relative liver weights at the end of the experiment are shown in Table 3Citation . The mean body weight of group 1 (AOM alone) was significantly lower (P < 0.001) than group 8 (untreated). Mean liver and relative liver weights of rats among groups 1–6 did not significantly differ. Dietary administration of 0.05% bezafibrate significantly elevated the mean liver and relative liver weights compared with the untreated control (P < 0.05 and P < 0.01, respectively).


View this table:
[in this window]
[in a new window]

  		Table 3 Effects of PPAR ligands on AOM-induced ACF formation in male F344 rats (experiment 2)

 
ACF analysis showed that administration of 0.05% troglitazone or bezafibrate caused a significant reduction in the numbers of ACF/colon (P < 0.01 or P < 0.001), as shown in Table 3Citation . Administration of 0.05% troglitazone significantly reduced aberrant crypts/focus (P < 0.005).

Experiment 3.
As shown in Table 4Citation , the final mean body weight of group 1 (AOM alone) was slightly higher than that of group 9 (untreated). The mean body weights of all groups did not significantly differ. Administration of 0.01% bezafibrate (group 5) significantly increased liver (P < 0.05) and relative liver weights (P < 0.01).


View this table:
[in this window]
[in a new window]

  		Table 4 Effects of PPAR ligands on AOM and/or DSS-induced ACF formation in male F344 rats (experiment 3)

 
ACF analysis (Table 4)Citation showed that treatment with 1% DSS and AOM (group 2) elevated the number of ACF/colon and aberrant crypts/focus. In groups 3–5, which were treated with 1% DSS, AOM, and 0.01% pioglitazone (group 3), 0.01% troglitazone (group 4), or 0.01% bezafibrate (group 5), both biomarkers were significantly smaller than those of group 2 (P < 0.05, P < 0.001, P < 0.005, P < 0.01, or P < 0.002). As summarized in Table 4Citation , the mean AgNORs index of group 1 (AOM alone) was significantly higher than group 9 (untreated; P < 0.001). DSS administration increased this value. Treatment with PPAR ligands (groups 3–5) significantly decreased AgNORs index compared with group 2 (P < 0.001).


   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
The results of the present study clearly indicated that PPAR ligands (either PPAR{gamma} or PPAR{alpha}) inhibited DDS-induced colitis and AOM-induced ACF. In addition, both ligands inhibited DSS/AOM-induced ACF formation, which are precursor lesions for colon carcinoma in the presence of colitis (7) . Our data on inhibition of chemically induced colitis are in agreement with those reported by Su et al. (27) . The results of experiments on ACF formation support those of Sarraf et al. (20) , in which troglitazone reduced the growth rate and induced differentiation of human colon tumor cell lines, both in culture and in nude mice. To our knowledge, this is the first report demonstrating that PPARs ligands (PPAR{gamma} or PPAR{alpha}) could inhibit colitis and ACF formation.

In Experiment 1, both troglitazone (a PPAR{gamma} ligand) and bezafibrate (a PPAR{alpha} ligand) effectively inhibited DSS-induced colitis. TFF2 and TFF3 are known to protect gastrointestinal injury (29) . In the large intestine with normal or pathological conditions, TFF3 but not TFF2 is expressed (29) . However, in the present study, PPAR ligands decreased the concentration of TFF2 but not TFF3 during the healing stage of colitis induced by DSS. Similar findings were reported in another model of colitis (35) . In Experiments 2 and 3, administration of bezafibrate significantly inhibited AOM-induced and DSS/AOM-induced colonic ACF. The treatment caused hepatomegaly, but no preneoplastic or neoplastic lesions were identified in the liver. In Experiment 3, the frequency of ACF in rats treated with DSS and AOM was greater than that of AOM alone, suggesting that colitis caused by DSS enhanced ACF formation initiated by AOM. Such enhancing effects of inflammation on colon carcinogenesis has also been reported by other researchers (31) .

Given the correlation between increased COX-2 expression and colonic carcinoma and/or inflammation, the chemopreventive effects of NSAIDs seems to be mediated, at least in part, by COX inhibition (36) . We demonstrated previously that indomethacin, a NSAID, inhibited colon tumorigenesis as well as colitis induced by a naturally occurring carcinogen, 1-hydroxyanthraquinone (37) . Interestingly, some NSAIDs act as peroxisome proliferators (28) , suggesting that they might also regulate gene expression as part of their chemopreventive mechanism. Inhibition of colonic inflammation and decrease in cell proliferation by PPARs ligands might be responsible for their chemopreventive effects on colitis-associated colon carcinogenesis, as seen in Experiment 3. Damage to DNA by reactive oxygen and nitrogen species contributes to inflammatory diseases, including colitis-related colon tumorigenesis (4) . PPAR{alpha} (24) and PPAR{gamma} (25) are involved in inflammation control, and both inhibit inducible nitric oxide synthase (26 , 38) . Several NSAIDs bind to PPAR{alpha} and PPAR{gamma} (28) . Their anti-inflammatory activities might be mediated through inhibition of COX-1 and/or COX-2. PPAR{alpha} could depress COX-2 induction (15) . Therefore, activation of this PPAR may contribute to the anti-inflammatory activity of these drugs. Furthermore, immunomodulation by the ligands (12) might contribute to inhibition of colitis and colon carcinogenesis.

PPAR{gamma} is aberrantly expressed in chemically induced rodent colon cancer and in several human colon cancer cell lines (23) . It can be up-regulated by treatment with butyrate, which induces differentiation of colon cancer cell line, Caco-2 cells (39) . Development of human colon cancer is often associated with mutations in PPAR{gamma} gene (40) . In addition, Lehmann et al. (28) reported that NSAIDs could bind and activate PPAR{gamma}, providing the molecular basis for the preventive effects of these drugs in colon carcinogenesis. In their study, NSAIDs also activated PPAR{alpha}. The results of the present study (experiments 2 and 3), in which ligands for PPAR{alpha} and PPAR{gamma} effectively prevented the development of ACF, lend support to the above findings. Although PPAR{gamma} is the predominant type of PPARs in the colon (16 , 17) and its expression increases upon differentiation in human colonic adenocarcinoma cells (41) , PPAR{alpha} is also expressed in the colon (16) and could differentiate malignant tumor cells (42) .

Recently, Suh et al. (22) reported that a new ligand for PPAR{gamma} (GW7845) inhibits nitrosomethylurea-induced mammary carcinogenesis in female rats. Subsequently, Mehta et al. (43) reported that troglitazone effectively inhibited preneoplastic mammary lesions in female BALB/c mice induced by 7,12-dimethylbenz[a]anthracene. Importantly, the inhibitory effects noted in their study were enhanced by treatment with a retinoid X receptor-selective retinoid, LG10068 (43) . Although the effects of PPAR{gamma} ligands on intestinal tumorigenesis are conflicting (18, 19, 20) , the results of the present study (experiments 2 and 3) suggest possible chemopreventive effects by PPAR{alpha} and PPAR{gamma} ligands in colon tumorigenesis with or without colitis.

Because troglitazone can cause hepatic dysfunction (44) , other PPAR{gamma} ligands, such as pioglitazone and GW7845, deserve further investigation with respective to their colon cancer chemopreventive effects. Interesting reports have been described recently. Human colon cancer cells express low levels of 13-S-hydroxyoctadecadienoic acid, a potent natural ligand of PPAR{gamma}, and 15-lipoxygenase-1, suggesting that 13-S-hydroxyoctadecadienoic acid production via 15-lipoxygenase-1 down-regulation plays a role in colon tumorigenesis (45) . As for PPAR{alpha} ligands, some (fibrates, phthalate ester plasticisers, pesticides, and hypolipidemic drugs) are considered to be nongenotoxic hepatic carcinogens in rodents (46) , although these data are not relevant to humans (47) . Thus, PPAR{alpha} ligands are also candidate chemopreventive agents against colon carcinogenesis.

In conclusion, we demonstrated in the present study that synthetic PPARs ligands (PPAR{alpha} and PPAR{gamma}) could inhibit DSS-induced colitis, AOM-induced ACF, and DSS/AOM-induced ACF. PPAR{gamma} ligands could induce growth arrest and differentiation in human colon cancer cell lines (41) . In addition, these ligands may inhibit tumor angiogenesis (48) . Combined together, the present results and those of previous studies suggest that PPAR activation may be beneficial through inhibition of the early and/or late stages of colon tumorigenesis.


   ACKNOWLEDGMENTS
 
We thank Ayumi Nagaoka for secretarial assistance. We also express our thanks to the staff of the Research Animal Facility.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by Grants-in-Aid for Scientific Research 12213131 and 10671782 from the Ministry of Education, Culture, Sports, and Technology of Japan; by a Grant-in Aid for the Second Term for a Comprehensive 10-year Strategy for Cancer Control from the Ministry of Health and Welfare, Japan; Grant HS-52260 for the Comprehensive Research Project on Health Sciences Focusing on Drug Innovation from the Japan Health Sciences Foundation; and Grant H2000-4 for Project Research from High-Technology Center of Kanazawa Medical University. Back

2 These two authors contributed equally to this work. Back

3 To whom requests for reprints should be addressed, at First Department of Pathology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan. E-mail: takutt{at}kanazawa-med.ac.jp Back

4 The abbreviations used are: DSS, dextran sodium sulfate; ACF, aberrant crypt foci; PPAR, peroxisome proliferator-activated receptor; NSAID, nonsteroidal anti-inflammatory drug; AOM, azoxymethane; TFF, trefoil factor; AgNOR, silver-stained nucleolar organizer region; COX, cyclooxygenase. Back

Received 11/ 8/00. Accepted 1/31/01.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Itzkowitz S. H. Colorectal cancer in inflammatory bowel disease Schmiegel W. Scholmerich J. eds. . Colorectal Cancer: Molecular Mechanisms, Premalignant State and Its Prevention, : 118-126, Kluwer Academic Publishers BV Dordrecht, the Netherlands 1999.
  2. Kakizoe T. Asian studies of cancer chemoprevention: latest clinical results. Eur. J. Cancer, 36: 1303-1309, 2000.
  3. Tanaka T., Kohno H., Murakami M., Shimada R., Kagami S. Colitis-related rat colon carcinogenesis induced by 1-hydroxyanthraquinone and methylazoxymethanol acetate. Oncol. Rep., 7: 501-508, 2000.[Medline]
  4. Maeda H., Akaike T. Review: nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Moscow), 63: 854-865, 1998.
  5. Iwai A., Iwasgita E. Changes in colonic inflammation induced by dextran sulfate sodium (DSS) during short- and long-term administration of rebamipide. Dig. Dis. Sci., 43: 143S-147S, 1998.[Medline]
  6. Hirono I., Kuhara K., Yamaji T., Hosaka S., Golberg L. Induction of colorectal squamous cell carcinomas in rats by dextran sulfate sodium. Carcinogenesis (Lond.), 3: 353-355, 1992.
  7. Whiteley L. O., Hudson L. J., Pretlow T. P. Aberrant crypt foci in the colonic mucosa of rats treated with a genotoxic and nongenotoxic colon carcinogen. Toxicol. Pathol., 24: 681-689, 1996.[Abstract/Free Full Text]
  8. Pretlow T. P., Barrow B. J., Ashton W. S., O’Riordan M. A., Pretlow T. G., Jurcisek J. A., Stellato T. A. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res., 51: 1564-1567, 1991.[Abstract/Free Full Text]
  9. Pretlow T. P., O’Riordan M. A., Somich G. A., Amini S. B., Pretlow T. G. Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate. Carcinogenesis (Lond.), 13: 1509-1512, 1992.[Abstract/Free Full Text]
  10. Bird R. P. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett., 93: 55-71, 1995.[Medline]
  11. Cooper H. S., Murthy S., Kido K., Yoshitake H., Flanigan A. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, ß-catenin and p53 expression and the role of inflammation. Carcinogenesis (Lond.), 21: 757-768, 2000.[Abstract/Free Full Text]
  12. Gelman L., Fruchart J-C., Auwerx J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell. Mol. Life Sci., 55: 932-943, 1999.[Medline]
  13. Auwerx J. PPAR{gamma}, the ultimate thrifty gene. Diabetologia, 42: 1033-1049, 1999.[Medline]
  14. Kersten S., Desvergne B., Wahli W. Roles of PPARs in health and disease. Nature (Lond.), 405: 421-424, 2000.[Medline]
  15. Vamecq J., Latruffe N. Medical significance of peroxisome proliferator-activated receptor. Lancet, 354: 141-148, 1999.[Medline]
  16. Mansen A., Guardiola-Diaz H., Rafter J. C. B., Gustafsson J-A. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem. Biophys. Res. Commun., 222: 844-851, 1996.[Medline]
  17. Jain S., Pulikuri S., Zhu Y., Qi C., Kanwar Y. S., Yeldandi A. V., Rao M. S., Reddy J. K. Differential expression of the peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am. J. Pathol., 153: 349-354, 1998.[Abstract/Free Full Text]
  18. Lefebvre A-M., Chen I., Desreumaux P., Najib J., Fruchart J-C., Geboes K., Briggs M., Heyman R., Auwerx J. Activation of the peroxisome proliferator-activated receptor {gamma} promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat. Med., 4: 1053-1057, 1998.[Medline]
  19. Saez E., Tontonoz P., Nelson M. C., Alvarez J. G. A., Ming U. T., Baird S. M., Thomazy V. A., Evans R. M. Activators of the nuclear receptor PPAR{gamma} enhance colon polyp formation. Nat. Med., 4: 1058-1061, 1998.[Medline]
  20. Sarraf P., Mueller E., Jones D., King F. J., DeAngelo D. J., Partridge J. B., Holden S. A., Chen L. B., Singer S., Fletcher C., Spiegelman B. M. Differentiation and reversal of malignant changes in colon cancer through PPAR{gamma}. Nat. Med., 4: 1046-1052, 1998.[Medline]
  21. Lehmann J. M., Moore L. B., Smith-Oliver T. A., Wilkison W. O., Willson T. M., Kliewer S. A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}). J. Biol. Chem., 270: 12953-12956, 1995.[Abstract/Free Full Text]
  22. Suh N., Wang Y., Williams C. R., Risingsong R., Gilmer T., Willson T. M., Sporn M. B. A new ligand for the peroxisome proliferator-activated receptor-{gamma} (PPAR-{gamma}), GW7845, inhibits rat mammary carcinogenesis. Cancer Res., 59: 5671-5673, 1999.[Abstract/Free Full Text]
  23. DuBois R. N., Gupta R., Brockman J., Reddy B. S., Krakow S. L., Lazar M. A. The nuclear eicosanoid receptor, PPAR{gamma}, is aberrantly expressed in colonic cancers. Carcinogenesis (Lond.), 19: 49-53, 1998.[Abstract/Free Full Text]
  24. Devchand P. R., Keller H., Peters J. M., Vazquez M., Gonzalez F. J., Wahli W. The PPAR{alpha}-leukotriene B4 pathway to inflammatory control. Nature (Lond.), 384: 39-43, 1996.[Medline]
  25. Jiang C., Ting A. T., Seed B. PPAR-{gamma} agonists inhibit production of monocyte inflammatory cytokines. Nature (Lond.), 391: 82-86, 1998.[Medline]
  26. Maggi L. B. J., Sadeghi H., Weigand C., Scarim A. L., Heitmeier M. R., Corbett J. A. Anti-inflammatory actions of 15-deoxy-{Delta}12,14-prostaglandin J2 and troglitazone. Diabetes, 49: 346-355, 2000.[Abstract]
  27. Su C. G., Wen X., Bailey S. T., Jiang W., Rangwala S. M., Keilbaugh S. A., Flanigan A., Murthy S., Lazar M. A., Wu G. D. A novel therapy for colitis utilizing PPAR-{gamma} ligands to inhibit the epithelial inflammation response. J. Clin. Investig., 104: 383-389, 1999.[Medline]
  28. Lehmann J. M., Lenhard J. M., Oliver B. B., Ringold G. M., Kliewer S. A. Peroxisome proliferator-activated receptors {alpha} and {gamma} are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem., 272: 3406-3410, 1997.[Abstract/Free Full Text]
  29. Wong W. M., Poulsom R., Wright N. A. Trefoil peptides. Gut, 44: 890-895, 1999.[Free Full Text]
  30. Mori H., Sugie S., Yoshimi N., Hara A., Tanaka T. Control of cell proliferation in cancer prevention. Mutat. Res., 428: 291-298, 1999.[Medline]
  31. Okayasu I., Ohkusa T., Kajiura K., Kanno J., Sakamoto S. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut, 39: 87-92, 1996.[Abstract/Free Full Text]
  32. Cook G. A., Yeomans N. D., Giraud A. S. Temporal expression of trefoil peptides in the TGF-{alpha} knockout mouse after gastric ulceration. Am. J. Physiol., 272: G1540-G1549, 1997.[Abstract/Free Full Text]
  33. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.[Medline]
  34. Tanaka T., Makita H., Kawamori T., Kawabata K., Mori H., Murakami A., Satoh K., Hara A., Ohigashi H., Koshimizu K. A xanthine oxidase inhibitor 1'-acetoxychavicol acetate inhibits azoxymethane-induced colonic aberrant crypt foci in rats. Carcinogenesis (Lond.), 18: 1113-1118, 1997.[Abstract/Free Full Text]
  35. Tran C. P., Cook G. A., Yeomans N. D., Thim L., Giraud A. S. Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut, 44: 636-642, 1999.[Abstract/Free Full Text]
  36. Wakabayashi K. NSAIDs as cancer preventive agents. Asian Pac. J. Cancer Prev., 1: 97-113, 2000.[Medline]
  37. Tanaka T., Kojima T., Yoshimi N., Sugie S., Mori H. Inhibitory effect of the non-steroidal anti-inflammatory drug, indomethacin on the naturally occurring carcinogen, 1-hydroxyanthraquinone in male ACI/N rats. Carcinogenesis (Lond.), 12: 1949-1952, 1991.[Abstract/Free Full Text]
  38. Colville-Nash P. R., Qureshi S. S., Willis D., Willoughby D. A. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1. J. Immunol., 161: 978-984, 1998.[Abstract/Free Full Text]
  39. Wachtershauser A., Loitsch S. M., Stein J. PPAR-{gamma} is selectively upregulated in Caco-2 cells by butyrate. Biochem. Biophys. Res. Commun., 272: 380-385, 2000.[Medline]
  40. Sarraf P., Mueller E., Smith W. M., Wright H. M., Kum J. B., Aaltonen L. A., de la Chapelle A., Spiegelman B. M., Eng C. Loss-of-function mutations in PPAR{gamma} associated with human colon cancer. Mol. Cell, 3: 799-804, 1999.[Medline]
  41. Kitamura S., Miyazaki Y., Shinomura Y., Kondo S., Kanayama S., Matsuzawa Y. Peroxisome proliferator-activated receptor {gamma} induces growth arrest and differentiation markers of human colon cancer cells. Jpn. J. Cancer Res., 90: 75-80, 1999.[Medline]
  42. Stier H., Fahimi H. D., Van Veldhoven P. P., Mannaerts G. P., Volkl A., Baumgart E. Maturation of peroxisomes in differentiating human hepatoblastoma cells (HepG2): possible involvement of the peroxisome proliferator-activated receptor {alpha} (PPAR {alpha}). Differentiation, 64: 55-66, 1998.[Medline]
  43. Mehta R. G., Williamson E., Patel M. K., Koeffler H. P. A ligand of peroxisome proliferator-activated receptor {gamma}, retinoids, and prevention of preneoplastic mammary lesions. J. Natl. Cancer Inst., 92: 418-423, 2000.[Abstract/Free Full Text]
  44. Watkins P. B., Whitcomb R. W. Hepatic dysfunction associated with troglitazone. N. Engl. J. Med., 338: 916-917, 1998.[Free Full Text]
  45. Shureiqi I., Wojno K. J., Poore J. A., Reddy R. G., Moussalli M. J., Spindler S. A., Greenson J. K., Normolle D., Hasan A. A. K., Lawrence T. S., Brenner D. E. Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis (Lond.), 20: 1985-1995, 1999.[Abstract/Free Full Text]
  46. Galloway S. M., Johnson T. E., Armstrong M. J., Ashby J. The genetic toxicity of the peroxisome proliferator class of rodent hepatocarcinogen. Mutat. Res., 448: 153-158, 2000.[Medline]
  47. Chevalier S., Roberts R. A. Perturbation of rodent hepatocyte growth control by nongenotoxic hepatocarcinogens: mechanisms and lack of relevance for human health. Oncol. Rep., 5: 1319-1327, 1998.[Medline]
  48. Xin X., Yang S., Kowalski J., Gerritsen M. E. Peroxisome proliferator-activated receptor {gamma} ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem., 274: 9116-9121, 1999.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
K. K. Das, M. Bajpai, Y. Kong, J. Liu, X. Geng, and K. M. Das
Mesalamine Suppresses the Expression of TC22, a Novel Tropomyosin Isoform Associated with Colonic Neoplasia
Mol. Pharmacol., July 1, 2009; 76(1): 183 - 191.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. J. Lee, J. Ju, S. Paul, J.-Y. So, A. DeCastro, A. Smolarek, M.-J. Lee, C. S. Yang, H. L. Newmark, and N. Suh
Mixed Tocopherols Prevent Mammary Tumorigenesis by Inhibiting Estrogen Action and Activating PPAR-{gamma}
Clin. Cancer Res., June 15, 2009; 15(12): 4242 - 4249.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. M. Necela, W. Su, and E. A. Thompson
Peroxisome Proliferator-activated Receptor {gamma} Down-regulates Follistatin in Intestinal Epithelial Cells through SP1
J. Biol. Chem., October 31, 2008; 283(44): 29784 - 29794.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Qiao, Y. Dai, Q. Gu, K. W. Chan, B. Zou, J. Ma, J. Wang, H. Y. Lan, and B. C.Y. Wong
Down-regulation of X-linked inhibitor of apoptosis synergistically enhanced peroxisome proliferator-activated receptor {gamma} ligand-induced growth inhibition in colon cancer
Mol. Cancer Ther., July 1, 2008; 7(7): 2203 - 2211.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. Panigrahy, A. Kaipainen, S. Huang, C. E. Butterfield, C. M. Barnes, M. Fannon, A. M. Laforme, D. M. Chaponis, J. Folkman, and M. W. Kieran
PPAR{alpha} agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition
PNAS, January 22, 2008; 105(3): 985 - 990.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
K. Yamazaki, M. Shimizu, M. Okuno, R. Matsushima-Nishiwaki, N. Kanemura, H. Araki, H. Tsurumi, S. Kojima, I B. Weinstein, and H. Moriwaki
Synergistic effects of RXR{alpha} and PPAR{gamma} ligands to inhibit growth in human colon cancer cells phosphorylated RXR{alpha} is a critical target for colon cancer management
Gut, November 1, 2007; 56(11): 1557 - 1563.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Ikeda, A. Tomimoto, K. Wada, T. Fujisawa, K. Fujita, K. Yonemitsu, Y. Nozaki, H. Endo, H. Takahashi, M. Yoneda, et al.
5-Aminosalicylic Acid Given in the Remission Stage of Colitis Suppresses Colitis-Associated Cancer in a Mouse Colitis Model
Clin. Cancer Res., November 1, 2007; 13(21): 6527 - 6531.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
W. Su, C. R. Bush, B. M. Necela, S. R. Calcagno, N. R. Murray, A. P. Fields, and E. A. Thompson
Differential expression, distribution, and function of PPAR-{gamma} in the proximal and distal colon
Physiol Genomics, August 20, 2007; 30(3): 342 - 353.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. R. Bush, J. M. Havens, B. M. Necela, W. Su, L. Chen, M. Yanagisawa, P. Z. Anastasiadis, R. Guerra, B. A. Luxon, and E. A. Thompson
Functional Genomic Analysis Reveals Cross-talk between Peroxisome Proliferator-activated Receptor {gamma} and Calcium Signaling in Human Colorectal Cancer Cells
J. Biol. Chem., August 10, 2007; 282(32): 23387 - 23401.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
L Dubuquoy, C Rousseaux, X Thuru, L Peyrin-Biroulet, O Romano, P Chavatte, M Chamaillard, and P Desreumaux
PPAR{gamma} as a new therapeutic target in inflammatory bowel diseases.
Gut, September 1, 2006; 55(9): 1341 - 1349.
[Full Text] [PDF]

Home page
 CarcinogenesisHome page
W.-P. Koh, J.-M. Yuan, D. Van Den Berg, S. A. Ingles, and M. C. Yu
Peroxisome proliferator-activated receptor (PPAR) {gamma} gene polymorphisms and colorectal cancer risk among Chinese in Singapore
Carcinogenesis, September 1, 2006; 27(9): 1797 - 1802.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Chen, B. M. Necela, W. Su, M. Yanagisawa, P. Z. Anastasiadis, A. P. Fields, and E. A. Thompson
Peroxisome Proliferator-activated Receptor {gamma} Promotes Epithelial to Mesenchymal Transformation by Rho GTPase-dependent Activation of ERK1/2
J. Biol. Chem., August 25, 2006; 281(34): 24575 - 24587.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
G Rogler
Significance of anti-inflammatory effects of PPAR{gamma} agonists?
Gut, August 1, 2006; 55(8): 1067 - 1069.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. J. Gunter, F. Canzian, S. Landi, S. J. Chanock, R. Sinha, and N. Rothman
Inflammation-related gene polymorphisms and colorectal adenoma.
Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1126 - 1131.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters
The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR)
Toxicol. Sci., April 1, 2006; 90(2): 269 - 295.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. Suzuki, H. Kohno, M. Suzui, N. Yoshimi, H. Tsuda, K. Wakabayashi, and T. Tanaka
An animal model for the rapid induction of tongue neoplasms in human c-Ha-ras proto-oncogene transgenic rats by 4-nitroquinoline 1-oxide: its potential use for preclinical chemoprevention studies
Carcinogenesis, March 1, 2006; 27(3): 619 - 630.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. He, Y. M. Sung, J. DiGiovanni, and S. M. Fischer
Thiazolidinediones Inhibit Insulin-Like Growth Factor-I-Induced Activation of p70S6 Kinase and Suppress Insulin-Like Growth Factor-I Tumor-Promoting Activity
Cancer Res., February 1, 2006; 66(3): 1873 - 1878.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Z. Gong, D. Xie, Z. Deng, R. M. Bostick, S. J. Muga, T. G. Hurley, and J. R. Hebert
The PPAR{gamma} Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas
Carcinogenesis, March 1, 2005; 26(3): 579 - 585.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. A. Jansson, A. Are, G. Greicius, I-C. Kuo, D. Kelly, V. Arulampalam, and S. Pettersson
The Wnt/{beta}-catenin signaling pathway targets PPAR{gamma} activity in colon cancer cells
PNAS, February 1, 2005; 102(5): 1460 - 1465.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
H Tilg and A Kaser
Diet and relapsing ulcerative colitis: take off the meat?
Gut, October 1, 2004; 53(10): 1399 - 1401.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. A. Ruiz, S. C. Kim, R. B. Sartor, and D. Haller
15-Deoxy-{Delta}12,14-prostaglandin J2-mediated ERK Signaling Inhibits Gram-negative Bacteria-induced RelA Phosphorylation and Interleukin-6 Gene Expression in Intestinal Epithelial Cells through Modulation of Protein Phosphatase 2A Activity
J. Biol. Chem., August 20, 2004; 279(34): 36103 - 36111.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. E. Lovett-Racke, R. Z. Hussain, S. Northrop, J. Choy, A. Rocchini, L. Matthes, J. A. Chavis, A. Diab, P. D. Drew, and M. K. Racke
Peroxisome Proliferator-Activated Receptor {alpha} Agonists as Therapy for Autoimmune Disease
J. Immunol., May 1, 2004; 172(9): 5790 - 5798.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
W K Leung, A H C Bai, V Y W Chan, J Yu, M W Y Chan, K-F To, J-R Wu, K-K Chan, Y-G Fu, F K L Chan, et al.
Effect of peroxisome proliferator activated receptor {gamma} ligands on growth and gene expression profiles of gastric cancer cells
Gut, March 1, 2004; 53(3): 331 - 338.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Nencioni, K. Lauber, F. Grunebach, L. Van Parijs, C. Denzlinger, S. Wesselborg, and P. Brossart
Cyclopentenone Prostaglandins Induce Lymphocyte Apoptosis by Activating the Mitochondrial Apoptosis Pathway Independent of External Death Receptor Signaling
J. Immunol., November 15, 2003; 171(10): 5148 - 5156.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Niho, M. Takahashi, T. Kitamura, Y. Shoji, M. Itoh, T. Noda, T. Sugimura, and K. Wakabayashi
Concomitant Suppression of Hyperlipidemia and Intestinal Polyp Formation in Apc-deficient Mice by Peroxisome Proliferator-activated Receptor Ligands
Cancer Res., September 15, 2003; 63(18): 6090 - 6095.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
L Jackson, W Wahli, L Michalik, S A Watson, T Morris, K Anderton, D R Bell, J A Smith, C J Hawkey, and A J Bennett
Potential role for peroxisome proliferator activated receptor (PPAR) in preventing colon cancer
Gut, September 1, 2003; 52(9): 1317 - 1322.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Bogazzi, F. Ultimieri, F. Raggi, D. Russo, P. Viacava, D. Cecchetti, A. Costa, S. Brogioni, C. Cosci, M. Gasperi, et al.
Changes in the Expression of the Peroxisome Proliferator-Activated Receptor {gamma} Gene in the Colonic Polyps and Colonic Mucosa of Acromegalic Patients
J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3938 - 3942.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Landi, V. Moreno, L. Gioia-Patricola, E. Guino, M. Navarro, J. de Oca, G. Capella, and F. Canzian
Association of Common Polymorphisms in Inflammatory Genes Interleukin (IL)6, IL8, Tumor Necrosis Factor {alpha}, NFKB1, and Peroxisome Proliferator-activated Receptor {gamma} with Colorectal Cancer ,
Cancer Res., July 1, 2003; 63(13): 3560 - 3566.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. A. Gupta, P. Sarraf, E. Mueller, J. A. Brockman, J. J. Prusakiewicz, C. Eng, T. M. Willson, and R. N. DuBois
Peroxisome Proliferator-activated Receptor {gamma}-mediated Differentiation: A MUTATION IN COLON CANCER CELLS REVEALS DIVERGENT AND CELL TYPE-SPECIFIC MECHANISMS
J. Biol. Chem., June 13, 2003; 278(25): 22669 - 22677.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. C. Desmond, J. C. Mountford, M. T. Drayson, E. A. Walker, M. Hewison, J. P. Ride, Q. T. Luong, R. E. Hayden, E. F. Vanin, and C. M. Bunce
The Aldo-Keto Reductase AKR1C3 Is a Novel Suppressor of Cell Differentiation That Provides a Plausible Target for the Non-Cyclooxygenase-dependent Antineoplastic Actions of Nonsteroidal Anti-Inflammatory Drugs
Cancer Res., January 15, 2003; 63(2): 505 - 512.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Greenwald
Cancer Prevention Clinical Trials
J. Clin. Oncol., September 15, 2002; 20(90001): 14s - 22.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
R. A. Gupta and R. N. Dubois
Controversy: PPARgamma as a target for treatment of colorectal cancer
Am J Physiol Gastrointest Liver Physiol, August 1, 2002; 283(2): G266 - G269.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Nencioni, F. Grunebach, A. Zobywlaski, C. Denzlinger, W. Brugger, and P. Brossart
Dendritic Cell Immunogenicity Is Regulated by Peroxisome Proliferator-Activated Receptor {gamma}
J. Immunol., August 1, 2002; 169(3): 1228 - 1235.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Shao, H. Sheng, and R. N. DuBois
Peroxisome Proliferator-activated Receptors Modulate K-Ras-mediated Transformation of Intestinal Epithelial Cells
Cancer Res., June 1, 2002; 62(11): 3282 - 3288.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
W E Rea, D C S Durrant, and D A R Boldy
Ulcerative colitis after statin treatment
Postgrad. Med. J., May 1, 2002; 78(919): 286 - 287.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
J. Auwerx
Nuclear Receptors: I. PPARgamma in the gastrointestinal tract: gain or pain?
Am J Physiol Gastrointest Liver Physiol, April 1, 2002; 282(4): G581 - G585.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Kopelovich, J. R. Fay, R. I. Glazer, and J. A. Crowell
Peroxisome Proliferator-activated Receptor Modulators As Potential Chemopreventive Agents
Mol. Cancer Ther., March 1, 2002; 1(5): 357 - 363.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. A. Gupta, J. A. Brockman, P. Sarraf, T. M. Willson, and R. N. DuBois
Target Genes of Peroxisome Proliferator-activated Receptor gamma in Colorectal Cancer Cells
J. Biol. Chem., August 3, 2001; 276(32): 29681 - 29687.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. A. Gupta, D. B. Polk, U. Krishna, D. A. Israel, F. Yan, R. N. DuBois, and R. M. Peek Jr.
Activation of Peroxisome Proliferator-activated Receptor gamma Suppresses Nuclear Factor kappa B-mediated Apoptosis Induced by Helicobacter pylori in Gastric Epithelial Cells
J. Biol. Chem., August 10, 2001; 276(33): 31059 - 31066.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanaka, T.
Right arrow Articles by Hosokawa, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanaka, T.
Right arrow Articles by Hosokawa, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online